Literature DB >> 11491295

Solution structures of C-1027 apoprotein and its complex with the aromatized chromophore.

T Tanaka1, S Fukuda-Ishisaka, M Hirama, T Otani.   

Abstract

C-1027 is one of the most potent antitumor antibiotic chromoproteins, and is a 1:1 complex of an enediyne chromophore having DNA-cleaving ability and a carrier apoprotein. The three-dimensional solution structures of the 110 residue (10.5 kDa) C-1027 apoprotein and its complex with the aromatized chromophore have been determined separately by homonuclear two-dimensional nuclear magnetic resonance methods. The apoprotein is mainly composed of three antiparallel beta-sheets: four-stranded beta-sheet (43-45, 52-54; 30-38; 92-94; 104-106), three-stranded beta-sheet (4-6; 17-22; 61-66), and two-stranded beta-sheet (70-72; 83-85). The overall structure of the apoprotein is very similar to those of other chromoprotein apoproteins, such as neocarzinostatin and kedarcidin. A hydrophobic pocket with approximate dimensions of 14 A x 12 A x 8 A is formed by the four-stranded beta-sheet and the three loops (39-42; 75-79; 97-100). The holoprotein (complex form with the aromatized chromophore) structure reveals that the aromatized chromophore is bound to the hydrophobic pocket found in the apoprotein. The benzodihydropentalene core of the chromophore is located in the center of the pocket and other substituents (beta-tyrosine, benzoxazine, and aminosugar moieties) are arranged around the core. Major binding interactions between the apoprotein and the chromophore are likely the hydrophobic contacts between the core of the chromophore and the hydrophobic side-chains of the pocket-forming residues, which is supplemented by salt bridges and/or hydrogen bonds. Based on the holoprotein structure, we propose possible mechanisms for the stabilization and the release of chromophore by the apoprotein.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11491295     DOI: 10.1006/jmbi.2001.4621

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  14 in total

1.  Inhibition of mouse embryonic carcinoma cell growth by lidamycin through down-regulation of embryonic stem cell-like genes Oct4, Sox2 and Myc.

Authors:  Hong-Ying Zhen; Qi-Hua He; Yong-Zhan Zhen; Shu-Ling Wang; Yi-Nan Liu; Wei-Hua Wu; Xiao-Yan Zhang; Ai-Li Lu; Li Shen
Journal:  Invest New Drugs       Date:  2010-07-02       Impact factor: 3.850

2.  Pharmacokinetics of C-1027 in mice as determined by TCA-RA method.

Authors:  You-Ping Liu; Quan-Sheng Li; Yu-Rong Huang; Mao-Jin Zhou; Chang-Xiao Liu
Journal:  World J Gastroenterol       Date:  2005-02-07       Impact factor: 5.742

3.  Factor VII light chain-targeted lidamycin shows intensified therapeutic efficacy for liver cancer.

Authors:  Qing Zhang; Xiujun Liu; Shuangshuang Xu; Caihong Li; Yang Zhang; Jie Yang; Junnian Zheng
Journal:  Cancer Biother Radiopharm       Date:  2012-05-31       Impact factor: 3.099

4.  Lidamycin shows highly potent cytotoxic to myeloma cells and inhibits tumor growth in mice.

Authors:  Yong-Zhan Zhen; Ya-Jun Lin; Yi Li; Yong-Su Zhen
Journal:  Acta Pharmacol Sin       Date:  2009-07       Impact factor: 6.150

5.  Engineered production of cancer targeting peptide (CTP)-containing C-1027 in Streptomyces globisporus and biological evaluation.

Authors:  Wenli Li; Xiuling Li; Tingting Huang; Qihui Teng; Ivana Crnovcic; Christoph Rader; Ben Shen
Journal:  Bioorg Med Chem       Date:  2016-04-08       Impact factor: 3.641

6.  Characterization of the SgcF epoxide hydrolase supporting an (R)-vicinal diol intermediate for enediyne antitumor antibiotic C-1027 biosynthesis.

Authors:  Shuangjun Lin; Geoffrey P Horsman; Yihua Chen; Wenli Li; Ben Shen
Journal:  J Am Chem Soc       Date:  2009-11-18       Impact factor: 15.419

7.  Enediyne lidamycin induces apoptosis in human multiple myeloma cells through activation of p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase.

Authors:  Yong-Zhan Zhen; Ya-Jun Lin; Bo-Yang Shang; Yong-Su Zhen
Journal:  Int J Hematol       Date:  2009-05-26       Impact factor: 2.490

8.  A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer.

Authors:  Shiming He; Chunyan Zhao; Hongyu Tao; Weijin Sheng; Ruijuan Gao; Xiujun Liu; Yongsu Zhen
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

9.  DBD-Hunter: a knowledge-based method for the prediction of DNA-protein interactions.

Authors:  Mu Gao; Jeffrey Skolnick
Journal:  Nucleic Acids Res       Date:  2008-05-31       Impact factor: 16.971

10.  The structure of a purple acid phosphatase involved in plant growth and pathogen defence exhibits a novel immunoglobulin-like fold.

Authors:  Svetlana Vladimirovna Antonyuk; Mariusz Olczak; Teresa Olczak; Justyna Ciuraszkiewicz; Richard William Strange
Journal:  IUCrJ       Date:  2014-02-28       Impact factor: 4.769

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.